Natco Pharma Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is VENETOCLAX, with a corresponding US DMF Number 40720.
Remarkably, this DMF maintains an Active status since its submission on November 15, 2024, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of December 18, 2024, and payment made on October 30, 2024, indicating their dedication to facilitating drug approvals, Categorized as Type II